8JD Stock Chart & Stats
€0.67
-€0.01(-0.67%)
At close: 4:00 PM EST
€0.67
-€0.01(-0.67%)
Day’s Range― - ―
52-Week Range€0.52 - €1.26
Previous CloseN/A
Volume0.00
Average Volume (3M)533.00
Market Cap
€25.22M
Enterprise Value€12.83
Total Cash (Recent Filing)€8.68M
Total Debt (Recent Filing)€5.09M
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
Mar 17, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding35,538,235
10 Day Avg. Volume1,600
30 Day Avg. Volume533
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.36
Price to Sales (P/S)18.17
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.24
Revenue Forecast (FY)€3.05M
Bulls Say, Bears Say
Bulls Say
Recent Revenue ReboundThe reported 417.1% revenue-growth figure indicates a substantial recent expansion in sales activity. If the rebound can be sustained, it would improve operating leverage and support commercialization investment, although historical volatility means durability still depends on execution.
Manageable LeverageDebt-to-equity remains moderate rather than indicating extreme leverage, which preserves some financial flexibility as Valbiotis develops its products. This provides a more manageable capital structure than the loss profile alone would suggest, although declining equity remains a concern.
Focused Nutrition-Health PlatformA defined focus on nutrition-health products for cardiometabolic and metabolic-health needs gives Valbiotis a coherent development platform. Research- and clinically evaluated formulations can support product credibility and commercialization across dietary-supplement or related channels.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow shows that the business is not currently self-funding. Continued cash burn can require repeated external capital, potentially limiting strategic flexibility and increasing the risk that future financing becomes a recurring feature of the operating model.
Deep And Persistent LossesPersistent losses and deeply negative margins indicate that current revenue is insufficient to absorb the company’s operating cost base. This weak profitability reduces internal funding capacity and makes the path to sustainable earnings dependent on substantial revenue growth or improved cost absorption.
Shrinking Equity And AssetsDeclining equity and assets reduce balance-sheet flexibility while persistently negative returns indicate that invested capital is not yet generating value. If losses continue, the company may face further dilution risk and have fewer internal resources available to support development and commercialization.
Valbiotis SA News
8JD FAQ
What was Valbiotis SA’s price range in the past 12 months?
Valbiotis SA lowest stock price was €0.52 and its highest was €1.26 in the past 12 months.
What is Valbiotis SA’s market cap?
Valbiotis SA’s market cap is €25.22M.
When is Valbiotis SA’s upcoming earnings report date?
Valbiotis SA’s upcoming earnings report date is Mar 17, 2027 which is in 168 days.
How were Valbiotis SA’s earnings last quarter?
Valbiotis SA released its earnings results on Mar 02, 2026. The company reported -€0.2 earnings per share for the quarter.
Is Valbiotis SA overvalued?
According to Wall Street analysts Valbiotis SA’s price is currently Overvalued.
Does Valbiotis SA pay dividends?
Valbiotis SA does not currently pay dividends.
What is Valbiotis SA’s EPS estimate?
Valbiotis SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valbiotis SA have?
Valbiotis SA has 35,538,235 shares outstanding.
What happened to Valbiotis SA’s price movement after its last earnings report?
Valbiotis SA reported an EPS of -€0.2 in its last earnings report. Following the earnings report the stock price went down -5.906%.
Which hedge fund is a major shareholder of Valbiotis SA?
Currently, no hedge funds are holding shares in DE:8JD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valbiotis SA
Valbiotis SA is a French company, established in 2014 and headquartered in Périgny, that specializes in the research and development of nutritional health products. Its primary focus is on preventing and managing metabolic and cardiovascular diseases. The company's pipeline includes several key candidates: TOTUM-63, currently in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, undergoing Phase II trials to address hypercholesterolemia; and TOTUM-854, which is in Phase II/III clinical development for arterial hypertension. Additionally, Valbiotis is developing TOTUM-448 to treat non-alcoholic fatty liver disease. The company maintains a strategic partnership with Nestlé Health Science.